YS YS Biopharma
- 0.738
- -0.012-1.60%
YS Biopharma News
YS Biopharma Receives 180 Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
YS Biopharma Receives 180 Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
YS Biopharma Reports 9M Results
Earnings Call Summary | YS Biopharma(YS.US) Q3 2024 Earnings Conference
The following is a summary of the YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript:Financial Performance:YS Biopharma reported a total revenue of RMB 438.1 million for the first nine month
YS Biopharma Co (YS.US): The 2024 Q3 financial report achieved revenue of US$238.15 million, with an expected value of US$22.84 million; earnings per share of -0.12 USD, with an expected value of -0.07 USD.
YS Biopharma Co (YS.US): The 2024 Q3 financial report achieved revenue of US$238.15 million, with an expected value of US$22.84 million; earnings per share of -0.12 USD, with an expected value of -0.07 USD.
YS Biopharma Co 9M 2024 EPS Loss Of RMB (1.04) Versus RMB (2.71) YoY
YS Biopharma Co 9M 2024 EPS Loss Of RMB (1.04) Versus RMB (2.71) YoY
YS Biopharma Co 9M 2024 Sales Of $61.9M
YS Biopharma Co 9M 2024 Sales Of $61.9M
Press Release: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
Dr. David Shao continued, "At the corporate level, since late 2023 we have embarked on a comprehensive series of initiatives aimed at fortifying our foundation for future growth.
YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, April 19, 2024 to discuss the financial results. Listeners may access the call by dialing the following numbers:
Chinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor
Tuesday, YS Biopharma Co Ltd (NASDAQ:YS) revealed interim results from the ongoing Phase 3 clinical trial of its next-generation PIKA Rabies Vaccine. The interim results indicate that the PIKA Rabies
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $230.5 million. Biophytis (NASD
YS Biopharma Highlights Interim Results Of Pivotal Phase 3 Clinical Study Of PIKA Rabies Vaccine; Says Results Indicate That The Pika Rabies Vaccine Has Successfully Met The Primary Endpoints Of The Trial
YS Biopharma Highlights Interim Results Of Pivotal Phase 3 Clinical Study Of PIKA Rabies Vaccine; Says Results Indicate That The Pika Rabies Vaccine Has Successfully Met The Primary Endpoints Of The T
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced positive interim results from the ongoing Phase 3 clinical trial (the "Phase 3 Trial" or the "Trial") of its next-generation PIKA Rabies Vaccine.
YS Biopharma Announces Full Repayment of $40M Loan Facility
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. Xilio Therapeutics (NASDAQ:XLO) stock moved
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. vTv Therapeutics (NASDAQ:VTVT) stock moved
YS Biopharma Announces Results of Extraordinary General Meeting Held on February 22, 2024
YS Biopharma Co., Ltd. (Nasdaq: YS) today announced the results of its extraordinary general meeting (the "EGM") held on February 22, 2024 in Hong Kong.
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements About the Meeting
GAITHERSBURG, Md., Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufa
Press Release: Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd. PR Newswire NEW YORK, Feb. 16, 2024 NEW YORK, Feb. 16, 2024
YS Biopharma Appoints Six New Members To Its Board, Effective February 13, 2024; Names Ajit Shetty As Chairperson
The six new directors are: Dr. Yuntao Cui; Dr. Jin Wang; Mr. Henry Chen; Mr. Haitao Zhao; Mr. Pierson Yue Pan; and Ms. Brenda Chunyuan Wu. In addition to the new appointments, the Board has elected Dr
Analysis
Price Target
No Data
